Contact
Locations
Search
Menu
Practices
Back
Overview
Accounting
Antitrust & Competition
Bankruptcy & Insolvency
Class Certification
Commercial Disputes
Damages
Data Science & Statistical Modeling
Energy, Climate & Natural Resources
Environmental, Social & Governance (ESG)
ERISA
Government & Corporate Investigations
Health Care
HEOR, Epidemiology & Market Access
Insurance
Intellectual Property
International Arbitration
Labor & Employment
Media, Entertainment & Communications
Privacy & Data Security
Securities, Financial Products & Institutions
Strategy, Policy & Analytics
Surveys & Experimental Studies
Tax
Technology
Transaction & Governance Litigation
Valuation
See full list of Practices & Focus Areas
Experts & Consultants
Back
Overview
Experts
Consultants
Insights
Back
Overview
Cases
AG Features
Videos
Publishing
Forum
Health Care Bulletin
News & Events
Back
Overview
News
Events
Press Releases
About
Back
Overview
Our Work
Locations
Diversity, Equity, and Inclusion
Pro Bono
Careers
Back
Overview
Career Path
What Is Economic Consulting?
Why Analysis Group
FAQs
Publishing
Insights
Publishing
Tolvaptan and Number Needed to Harm in Autosomal Dominant Polycystic Kidney Disease
Kidney Medicine, 2024
View abstract
Authors
Betts KA
, Nunna S, Kumar R,
Nie X
, Fernandes AW
Practice
HEOR, Epidemiology & Market Access
Collapse
